12th-14th September, 2016

London

Day One
Tuesday 13th September 2016

Day Two
Wednesday 14th September 2016

08:00
Breakfast & Networking

08:50
Chairman’s Opening Remarks

Making the Translational Leap Between Pre-Clinical & Clinical

09:00
Alzheimer’s Disease Therapeutics: Possibilities & Pitfalls

  • Eric Karran Vice President, Distinguished Research Fellow, Foundational Neuroscience Center, AbbVie

Synopsis

  • Addressing the amyloid cascade hypothesis, its influence in both academic and industrial research and the resulting number of drugs that have reached clinical testing in man
  • Exploring the reasons behind why none of these drugs have met their primary outcome measures
  • Reviewing the prospects of drugs currently in clinical testing

09:30
Why Biomarkers are Key Prior to Pivotal Trials to Guide Dose & Efficacy in AD Patients

  • Birgitte Søgaard Divisional Director, Clinical & Quantitative Pharmacology, Lundbeck

Synopsis

  • Examining issues related to biomarkers guiding the dose
  • Evaluating the consequences of having the wrong biomarkers
  • Exploring the consequences of different biomarkers across the AD field

10:00
Back-Translation of Cortical EEG Biomarkers from Humans to Mice for Drug Discovery in Alzheimer’s Disease: The PharmaCog Project Way

  • Claudio Babiloni Associate Professor of Physiology, University of Rome “La Sapienza”

Synopsis

  • Testing translational values of electroencephalographic (EEG) and
  • other biomarkers in Alzheimer’s disease
  • Examining markers of on-going cortical EEG rhythms that reflect
  • prodromal AD processes in amnesic mild cognitive impairment
  • subjects
  • Observing analogous abnormalities in the EEG markers in transgenic
  • mouse models of AD
  • Discussing a translational value of EEG markers for an early evaluation of AD modifying drugs

10:30
Morning Refreshments

Driving Success in the Clinical Neurodegenerative Landscape

11:00
Maximising the Translatability of Early Development Proof of Principle Trials

  • Johan Luthman Vice President, Neuroscience Clinical Development, Eisai

Synopsis

  • Understanding how to design and execute translational PoP trials
  • Improving PoP endpoints to provide the most valuable data to inform the potential success of later phases
  • How to best translate pre-clinical research into early stage PoP studies to reliably reproduce drug effect

11:30
Harnessing Big Data & Wearable Technology to Advise Clinical Readouts

  • Carsten Spannhuth Global Program Medical Director & Digital Development Medical Adviser, Novartis

Synopsis

  • Examining wearable devices for frequent phenotyping of patients to support surrogate biomarker studies
  • Understanding what is the most meaningful data to discern changes in disease progression
  • How to utilise wearable tech data measures to show modification in cognition and function
  • Debating whether or not wearable tech can ultimately replace surrogate biomarkers
  • Does big data provide as much indication of disease modification as imaging data and biomarker tracking?
  • Addressing the regulatory requirements for the increased use of wearable tech in neuroscience clinical studies

12:00
Panel Discussion: Addressing the Clinical Trial Landscape

  • Carsten Spannhuth Global Program Medical Director & Digital Development Medical Adviser, Novartis
  • Johan Luthman Vice President, Neuroscience Clinical Development, Eisai
  • Robert O’Donnell Vice President, Global Regulatory Head, Johnson & Johnson

Synopsis

  • Are wearable devices the way forward and can they aid surrogate biomarker studies?
  • How can we best use negative trial data to drive clinical success?
  • How do you translate early phase markers of engagement into more meaningful studies?
  • What make the best clinical endpoints?
  • What do we really need to make a trial successful?
  • How many studies do we need in order to validate the prevention of disease development?
  • Addressing regulatory challenges and requirements for neurodegenerative drug candidates
  • Debating the reimbursement paradigm for neurodegenerative disease-modifying therapies

12:45
Networking Lunch

Next Generation Therapeutic Approaches for Targeting Neurodegenerative Diseases

13:45
Targeting the Spread of Pathology in Neurodegenerative Diseases

Synopsis

  • Elucidating biological triggers in the spread of neurodegeneration
  • Advancing modelling of pathological spread to identify viable therapeutic targets
  • Identifying novel strategies for targeting the spread of pathology to block the progression of neurodegeneration

14:15
The Precision Medicine Paradigm in Neurodegenerative Diseases

  • Harald Hampel Professor, AXA Research Fund & UPMC Chair, Sorbonne Universities, Pierre & Marie Curie University

Synopsis

  • Translating and facilitating the precision medicine paradigm in the neurodegeneration field area
  • Analysing advances in genetic methodologies and their impact in neurodegenerative research: Whole genome sequencing, whole exome sequencing and their application in systems biology
  • Understanding how precision medicine can inform translational drug discovery and development in neuroscience

14:45
Afternoon Refreshments

15:15
From the Bench to the Bedside: Exploiting Targets for Therapeutic Intervention in Neurodegeneration

  • Tiago Outeiro Professor & Director, Department of Neurodegeneration and Neurorestoration, University Medical Center Gottingen

Synopsis

  • Addressing protein misfolding as a common hallmark in neurodegeneration
  • Analysing protein aggregation: Innocent bystander or culprit?
  • Discussing novel molecular players in neurodegeneration
  • Making the leap from mechanism to therapies

15:45
Opportunities & Challenges in the Biotech World

Synopsis

  • Identifying what’s needed in order to provide sufficient evidence of drug efficacy and safety to advance through the developmental pipeline
  • Overcoming pre-clinical resourcing issues
  • Identifying valuable markers to advance drug discovery and development

16:15
Chairman’s Closing Remarks

16:20
Close of Day Two & End of Conference